



MAY 23 1984

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
National Institutes of Health

Memorandum

Date May 17, 1984
From Chief, Infectious Diseases Branch, IRP, NINCDS
Subject Receipt of HTLV-III
To Chief, Laboratory of Tumor Cell Biology, NCI
Building 37, Room 6A09

5-31 Ann
call: use HTLV-III
LAV is identical
file


On Tuesday, May 15, 1984 Drs. Madden, Graveli and I met with Dr. Ann Sliski in my Office. We reviewed some of the studies which we have been conducting and the general areas which we will be investigating with the HTLV-III virus. These areas include for example:

1. Seroepidemiologic studies of prospectively collected sera from homosexuals, pre AIDS, and AIDS patients in Southern California. We have already published on these patients with investigators at UCLA.
2. Seroepidemiologic studies of homosexuals, AIDS, and other patient groups in conjunction with the NCI Epidemiologic Group of Drs. Bigger and Goedert.
3. Attempts to isolate virus from prospectively collected specimens from UCLA.
4. Attempts to isolate virus and determine antibody levels in patients with central nervous system involvement and AIDS.
5. Animal studies in various subhuman primates and other experimental animals using both AIDS and SAIDS material.
6. Electronmicroscopy studies of SAIDS and AIDS specimens.

We plan to try to develop IgM and capture tests. We will keep you informed of our work and will forward copies of our abstracts and manuscripts to you for your comments prior to submission for presentation or publication.

We have been in contact with Dr. Chermann since his presentation at the meetings in February at Park City, Utah. As you know, we presented reports on SAIDS at that meeting. We recently received frozen LAV virus from Dr. Chermann. Dr. Graveli will go to his Laboratory on May 28, 1984, as previously agreed, to conduct some joint studies on virus isolation and antibody determinations. We will probably include the LAV in our studies along with HTLV-III unless it is determined that the two viruses are identical.

We signed the agreement concerning the use of HTLV and we received the infected and control cultures. We have also requested the plates from Dr. Ting at Biotech and the control sera from Dr. Serang at Litton. We understand it may be necessary to do Western Blots for appropriate serological studies. We appreciate your willingness to share the HTLV-III with us.


John L. Sever, M.D., Ph.D.